Johnson & Johnson (NYSE: JNJ) kicked off on Friday, down -0.41% from the previous trading day, before settling in for the closing price of $219.57. Over the past 52 weeks, JNJ has traded in a range of $141.50-$219.75.
Healthcare Sector giant saw their annual sales surged by 0.55% over the last five years. While this was happening, its average annual earnings per share was recorded 8.29%. With a float of $2.41 billion, this company’s outstanding shares have now reached $2.41 billion.
Johnson & Johnson (JNJ) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Johnson & Johnson is 0.12%, while institutional ownership is 74.26%. The most recent insider transaction that took place on Nov 26 ’25, was worth 257,688. In this transaction Director of this company bought 1,250 shares at a rate of $206.15, taking the stock ownership to the 1,849 shares. Before that another transaction happened on Nov 26 ’25, when Company’s 10% Owner sold 6,337 for $10.03, making the entire transaction worth $63,560. This insider now owns 4,040,861 shares in total.
Johnson & Johnson (JNJ) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 2.04 earnings per share (EPS), higher than consensus estimate (set at 2.01) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.52% during the next five years compared to 0.55% growth over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Take a look at Johnson & Johnson’s (JNJ) current performance indicators. Last quarter, stock had a quick ratio of 0.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.72. Likewise, its price to free cash flow for the trailing twelve months is 26.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.36, a number that is poised to hit 2.47 in the next quarter and is forecasted to reach 11.48 in one year’s time.
